title: Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic stem cell transplantation in CML.
authors.forename: M
authors.initials: M
authors.lastname: Weisser
authors.forename: C
authors.initials: C
authors.lastname: Schmid
authors.forename: C
authors.initials: C
authors.lastname: Schoch
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
authors.forename: H J
authors.initials: HJ
authors.lastname: Kolb
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate